Compstatins: the dawn of clinical C3-targeted complement inhibition

Christina Lamers, Dimitrios C. Mastellos, Daniel Ricklin, John D. Lambris

Open source

DOI: 10.1016/j.tips.2022.01.004
Published: 2022-08
Container: Trends in Pharmacological Sciences
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.tips.2022.01.004,
  title = {Compstatins: the dawn of clinical C3-targeted complement inhibition},
  author = {Christina Lamers and Dimitrios C. Mastellos and Daniel Ricklin and John D. Lambris},
  year = {2022},
  journal = {Trends in Pharmacological Sciences},
  doi = {10.1016/j.tips.2022.01.004},
  url = {https://doi.org/10.1016/j.tips.2022.01.004}
}

RIS

TY  - JOUR
TI  - Compstatins: the dawn of clinical C3-targeted complement inhibition
AU  - Christina Lamers
AU  - Dimitrios C. Mastellos
AU  - Daniel Ricklin
AU  - John D. Lambris
PY  - 2022
JO  - Trends in Pharmacological Sciences
DO  - 10.1016/j.tips.2022.01.004
UR  - https://doi.org/10.1016/j.tips.2022.01.004
ER  -

APA

Lamers, C., Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2022). Compstatins: the dawn of clinical C3-targeted complement inhibition. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2022.01.004

Source records

crossref · retrieved 2026-09-26T22:02:41.828Z